Alnylam Pharmaceuticals
(NASDAQ) ALNY
Alnylam Pharmaceuticals Financials at a Glance
Market Cap
$39.51B
Revenue (TTM)
$4.29B
Net Income (TTM)
$577.22M
EPS (TTM)
$4.21
P/E Ratio
70.36
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Price
$296.07
Volume
41,899
Open
$309.66
Price
$296.07
Volume
41,899
Open
$309.66
Previous Close
$296.07
Daily Range
$296.02 - $310.12
52-Week Range
$245.96 - $495.55
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Price
$296.07
Volume
41,899
Open
$309.66
Previous Close
$296.07
Daily Range
$296.02 - $310.12
52-Week Range
$245.96 - $495.55
ALNY News
Best Biotech ETFs to Buy in 2026
ALNY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Alnylam Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
2,500
CEO
Yvonne L. Greenstreet, MD, MBA
Website
www.alnylam.comHeadquarters
Cambridge, MA 02142, US
ALNY Financials
Key Financial Metrics (TTM)
Gross Margin
81%
Operating Margin
18%
Net Income Margin
13%
Return on Equity
97%
Return on Capital
20%
Return on Assets
11%
Earnings Yield
1.42%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$39.51B
Shares Outstanding
133.43M
Volume
41.90K
Avg. Volume
1.26M
Financials (TTM)
Gross Profit
$3.04B
Operating Income
$501.58M
EBITDA
$557.24M
Operating Cash Flow
$524.08M
Capital Expenditure
$58.70M
Free Cash Flow
$465.38M
Cash & ST Invst.
$2.91B
Total Debt
$1.28B
Alnylam Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.17B
+96.4%
Gross Profit
$956.05M
+82.8%
Gross Margin
81.91%
N/A
Market Cap
$39.51B
N/A
Market Cap/Employee
$17.72M
N/A
Employees
2,230
N/A
Net Income
$205.99M
+458.4%
EBITDA
$152.37M
+1230.1%
Quarterly Fundamentals
Net Cash
$1.74B
+2028.4%
Accounts Receivable
$883.96M
+111.5%
Inventory
$84.03M
+28.1%
Long Term Debt
$1.23B
-52.7%
Short Term Debt
$45.66M
-64.3%
Return on Assets
11.25%
N/A
Return on Invested Capital
19.90%
N/A
Free Cash Flow
$48.67M
+138.2%
Operating Cash Flow
$70.50M
+159.6%